Relovair

GlaxoSmithKline's Q1 Call Has Muted Mention Of Relovair

GlaxoSmithKline's Q1 Call Has Muted Mention Of Relovair

Seeking Alpha

Breathe Easy: Relovair Program Complete, Data Solid

Breathe Easy: Relovair Program Complete, Data Solid

Motley Fool

GSK lung drug has mixed results but filing on track

GSK lung drug has mixed results but filing on track

Reuters

Theravance: A $1.5 Billion Company With An $8 Billion Product

Theravance: A $1.5 Billion Company With An $8 Billion Product

Seeking Alpha

For Theravance Investors, GlaxoSmithKline Won't Be The Answer

For Theravance Investors, GlaxoSmithKline Won't Be The Answer

Seeking Alpha

Theravance shares make modest rebound

Theravance shares make modest rebound

Marketwatch

Theravance Shares Slide on Lung Drug Deaths

Theravance Shares Slide on Lung Drug Deaths

TheStreet.com

GSK Sets Stage for Big Late-Stage Drug Events, Potential Blockbusters

GSK Sets Stage for Big Late-Stage Drug Events, Potential Blockbusters

Motley Fool

GlaxoSmithKline Investors Nervous After Relovair Reports Mixed Data

GlaxoSmithKline Investors Nervous After Relovair Reports Mixed Data

Seeking Alpha

New GSK lung drug hits most targets in two studies

New GSK lung drug hits most targets in two studies

Yahoo/Reuters